Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 3/20 | 0.46 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.44 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30079514 | 1.00 | CYP11B1 (0.47) | CYP11B1CYP11B2ARPGRGLA | |
| SCHEMBL15832052 | 0.88 | SLC22A12 (0.52) | ARGAAPOLBNPC1RAB9A | |
| SCHEMBL2539990 | 0.84 | CYP11B1 (0.58) | CYP11B1CYP11B2ARPGRGLA | |
| SCHEMBL188284 | 0.82 | MAOB (0.55) | POLBPLA2G7NPC1RAB9AMAOB | |
| SCHEMBL111126 | 0.81 | PGR (0.63) | CYP11B1CYP11B2ARPGRGLA | |
| SCHEMBL28704253 | 0.81 | MAOB (0.48) | CYP11B1CYP11B2ARPGRMEN1 | |
| SCHEMBL7535762 | 0.81 | MAOB (0.51) | CYP11B1CYP11B2ARPGRMEN1 | |
| SCHEMBL1154814 | 0.81 | MAOB (0.58) | NPC1RAB9AMAOB | |
| SCHEMBL9560109 | 0.81 | MAOB (0.57) | ARPGRGLAMEN1KMT2A | |
| SCHEMBL6212996 | 0.80 | CPS1 (0.40) | MEN1KMT2AGAAPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109952289-B | TRPV4 antagonists | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-109952289-A | TRPV4 antagonist | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-06-28 | — | — | CN | claimed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-29 | — | — | US | disclosed |
| WO-2024199444-A1 | HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024175925-A1 | MC2R MODULATOR COMPOUNDS | Omass Therapeutics Limited (GB) | 2024-08-29 | — | — | WO | disclosed |
| CN-114423757-B | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-4326257-A1 | AZETIDINYL-ACETAMIDES AS CXCR7 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| WO-2006063708-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
| EP-1627871-A1 | CYCLIC AMINOPHENYL SULFAMATE DERIVATIVE | Teikoku Hormone Mfg. Co., Ltd. (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-6380218-B1 | FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| EP-0971894-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Products Inc. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998045268-A1 | NICOTINAMIDE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-10-15 | — | — | WO | disclosed |
| WO-1994025461-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA3, GABRA5, GABRA1 | CYP11B1 253/4885CYP11B2 374/4885AR 240/4885 |
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | CYP11B1 796/4885CYP11B2 629/4885AR 336/4885 |
| US-20060189625-A1 | Cyclic aminophenyl sulfamate derivative | SHBG, STS, ARSA | CYP11B1 63/4885CYP11B2 92/4885AR 16/4885 |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | CYP11B1 303/4885CYP11B2 479/4885AR 356/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | CYP11B1 12/4885CYP11B2 6/4885AR 1495/4885 |
| US-12286428-B2 | Tricyclic heteroaryl compounds useful as IRAK4 inhibitors | IRAK4, IRAK1, IRAK3 | CYP11B1 1428/4885CYP11B2 2077/4885AR 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.